- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Virtual screening.
Displaying page 1 of 1.
EudraCT Number: 2005-001866-15 | Sponsor Protocol Number: 1182.71 | Start Date*: 2007-07-12 |
Sponsor Name:Boehringer Ingelheim France SAS | ||
Full Title: A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in three-clas... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GR (Completed) PT (Prematurely Ended) IT (Prematurely Ended) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004840-51 | Sponsor Protocol Number: EIP19-NFD-401 | Start Date*: 2019-06-26 | |||||||||||
Sponsor Name:EIP Pharma, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | |||||||||||||
Medical condition: Early-Stage Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006117-32 | Sponsor Protocol Number: TPV/rSimplification Regimen | Start Date*: 2007-02-05 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: Tipranavir/ritonavir 500/100 mg bid as a simplification strategy in HIV-1 infected subjects with an ongoing Tipranavir 500mg/Ritonavir 200mg bid regimen and undetectable viral load. | |||||||||||||
Medical condition: patients affected by HIV with negative viremia values | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002640-70 | Sponsor Protocol Number: 20-HMedIdeS-19 | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Hansa Biopharma AB | |||||||||||||
Full Title: A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase tre... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002209-25 | Sponsor Protocol Number: 67652000PCR3002 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Parti... | |||||||||||||
Medical condition: Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003726-23 | Sponsor Protocol Number: 1346-0013 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) FI (Completed) CZ (Completed) BE (Completed) LT (Completed) PT (Completed) AT (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003744-84 | Sponsor Protocol Number: 1346-0012 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) NL (Completed) FR (Completed) SK (Completed) ES (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001652-36 | Sponsor Protocol Number: UC-0105/1304 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer | |||||||||||||
Medical condition: Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001653-27 | Sponsor Protocol Number: UC_0105-1305_/_IFCT_1301 | Start Date*: 2014-07-24 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer | |||||||||||||
Medical condition: Patients with metastatic non small cell lung cancer (NSCLC) in 1st line chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003760-11 | Sponsor Protocol Number: 1346-0011 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) PL (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
